Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Zomepirac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zomepirac SCHEMBL11172041 | 0.99 | CYP1A2 (0.97) | CYP1A2ALDH1A1LMNATSHRSMN1; SMN2 | |
| Zomepirac SCHEMBL11296453 | 0.96 | CYP1A2 (0.93) | CYP1A2ALDH1A1LMNATSHRSMN1; SMN2 | |
| Zomepirac SCHEMBL11495795 | 0.96 | CYP1A2 (0.93) | CYP1A2ALDH1A1LMNATSHRSMN1; SMN2 | |
| Zomepirac SCHEMBL9655800 | 0.87 | PTGS2 (0.97) | CYP1A2ALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL10905144 | 0.86 | ALDH1A1 (0.75) | CYP1A2ALDH1A1LMNATSHRSMN1; SMN2 | |
| Zomepirac SCHEMBL7204056 | 0.86 | PTGS2 (0.95) | CYP1A2ALDH1A1LMNATSHRSMN1; SMN2 | |
| Zomepirac SCHEMBL25735 | 0.85 | PTGS2 (1.00) | CYP1A2ALDH1A1LMNATSHRSMN1; SMN2 | |
| Zomepirac SCHEMBL11495798 | 0.85 | PTGS2 (1.00) | CYP1A2ALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL10905829 | 0.85 | PTGS2 (0.80) | CYP1A2ALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL12608966 | 0.85 | PTGS2 (0.80) | CYP1A2ALDH1A1LMNATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119671473-A | Substation large-scale mechanical operation safety control method and system based on space environment modeling | 福建亿榕信息技术有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20210113469-A1 | SUSTAINED RELEASE COMPOSITIONS USING WAX-LIKE MATERIALS | TRUIST BANK, AS ADMINISTRATIVE AGENT FOR THE SECURED PARTIES | 2021-04-22 | — | — | US | disclosed |
| US-10888521-B2 | Sustained release compositions using wax-like materials | FARNAM COMPANIES, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-9561274-B2 | Treatment and prevention of cancer with HMGB1 antagonists | UNIVERSITY OF HAWAII (US) | 2017-02-07 | — | — | US | disclosed |
| US-20140127134-A1 | TREATMENT AND PREVENTION OF CANCER WITH HMGB1 ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-08 | — | — | US | disclosed |
| US-20130089608-A1 | Sustained Release Pharmaceutical Compositions for Highly Water Soluble Drugs | FARNAM COMPANIES, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012170742-A2 | TREATMENT AND PREVENTION OF CANCER WITH HMGB1 ANTAGONISTS | UNIVERSITY OF HAWAII (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8221792-B2 | Sustained release pharmaceutical compositions for highly water soluble drugs | FARNAM COMPANIES, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110118243-A1 | ANTI-INFLAMMATORY DRUG DELIVERY SYSTEM | CHAMBERS LYNN | 2011-05-19 | — | — | US | disclosed |
| EP-0546676-A1 | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug | MCNEILAB, INC. (US) | 1993-06-16 | — | — | EP | disclosed |
| US-4599359-A | POTENTIATION | Cooper, Stephen A. (US) | 1986-07-08 | — | — | US | disclosed |
| US-4528382-A | Imidoyl substituted pyrroles | MCNEILAB, INC. (US) | 1985-07-09 | — | — | US | disclosed |
| EP-0061287-B1 | ANALGESIC POTENTIATION | McNeilab, Inc. (US) | 1984-08-15 | — | — | EP | disclosed |
| WO-1984002273-A1 | ANALGESIC COMBINATIONS | SANDOZ AG (CH) | 1984-06-21 | — | — | WO | disclosed |
| EP-0111456-A1 | Analgesic combinations | Cooper, Stephen A. Dr. (US) | 1984-06-20 | — | — | EP | disclosed |
| EP-0061287-A1 | Analgesic potentiation | McNeilab, Inc. (US) | 1982-09-29 | — | — | EP | disclosed |
| US-4338324-A | COMBINATION OF ZOMEPIRAC AND BUTORPHANOL | MCNEILAB, INC. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4294760-A | Preparation of 5-(arylcyanohydroxymethyl)-1-loweralkylpyrrole-2-acetic acid derivatives | MCNEILAB, INC. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4255335-A | Preparation of 5-aroyl-1-loweralkylpyrrole-2-acetic acid derivatives | MCNEILAB, INC. (US) | 1981-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089608-A1 | Sustained Release Pharmaceutical Compositions for Highly Water Soluble Drugs | ABCG2, ABCB11, SLC7A5 | PTGS2 124/4885CYP1A2 554/4885ALDH1A1 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.